$20M renewal of 4-decade-long federal grant to Hutch scientists
May 31, 2018
| By Susan Keown / Fred Hutch News Service
The National Cancer Institute has awarded Hutch with five years and nearly $20 million in funding for research to develop better therapies for people with blood cancers. The award is the latest renewal of a grant that has been funded continuously for more than 40 years.
T cells bearing a new engineered protein boost immunotherapy’s effectiveness in laboratory models of AML, ovarian, pancreatic cancers
April 16, 2018
| By Rachel Tompa / Fred Hutch News Service
In an effort to improve the efficacy of immunotherapy for solid tumors, Fred Hutch researchers have engineered a new type of protein that can rewire a 'kill switch' to stimulate T cells' activity instead.
Immunology research leader named 2018 recipient of Richard V. Smalley, M.D., Memorial Award and Lectureship
March 23, 2018
On March 22, the Society for Immunotherapy of Cancer announced Fred Hutch's Dr. Philip Greenberg as the 2018 recipient of the Richard V. Smalley, M.D., Memorial Award and Lectureship, the society’s highest honor.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.